Avenova for the Treatment of Viral Conjunctivitis
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- Number of Participants With Clinical Resolution of Viral Conjunctivitis
研究概览
简要总结
The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
盲法说明
A second investigator will randomize the patient to Treatment vs Placebo on initial visit. This "second investigator" will not be involved in screening or follow-up patient visits. At the end of the study the patient arms will be unmasked.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients presenting to the Bascom Palmer Eye Institute
- •Clinical diagnosis of viral conjunctivitis
- •Symptoms less than 1 week duration
排除标准
- •history of allergic conjunctivitis
- •history of herpetic eye disease
- •concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating)
- •Immunocompromised / Immunosuppressed patients
- •Patients with HIV
- •pregnant women
- •prisoners
- •adults who are unable to provide consent
结局指标
主要结局
Number of Participants With Clinical Resolution of Viral Conjunctivitis
时间窗: Up to 8 days
This is the number of participants who on day 7 (+/-1 days) had on clinical examination a 0 or 1 on the follicular conjunctivitis scale and 0 or 1 on the conjunctival injection scale.
次要结局
- Number of Participants With Symptomatic Resolution of Viral Conjunctivitis(Up to 8 days)
- Number of Participants With Undetectable Adenoviral DNA(Up to 8 days)
研究者
Wendy Lee
Associate Professor
University of Miami